Krishnan, the Chief Executive Officer of Krystal Biotech, has executed a sale of company stock valued at $7.7 million. The transaction reflects a significant movement of shares within the biotechnology firm, although specific details regarding the number of shares sold or the reasons for the sale were not disclosed. This development comes as Krystal Biotech continues to advance its portfolio of gene therapies. The sale is part of routine stock trading activities by executives in publicly traded companies.
Related Articles
Don't miss out on breaking stories and in-depth articles.